It was reported that high expression of IGF2BP3 in patients with glioma significantly reduced survival time, which was also associated with poor prognosis, suggesting that IGF2BP3 might be used as a potential prognostic biomarker for gliomas (Liu et al., 2021b; Sun et al., 2021; Xiong et al., 2022). Here, IGF2BP3 is linked to central nervous system cancer.